Continued growth in the development of large molecule therapeutics has constrained resources for in vivo studies and in vitro sample analysis. In addition, the COVID-19 pandemic has brought renewed urgency to vaccine research and development, emphasizing a need to protect the world against existing, re-emerging and emerging pathogens and accelerate …
Long COVID Q&A: 4 things to know about COVID cognitive dysfunction
Long COVID is a colloquial term used to describe the lingering health symptoms some patients experience after contracting the COVID-19 virus. While the majority of people fully recover from the virus, some “long-hauler” patients report long COVID symptoms ranging from general fatigue to headaches and brain fog, also known as …
Labcorp Drug Development on the leading edge of revitalizing Leeds’ Temple district
As a regional leader of life science innovation in the U.K., the city of Leeds abounds in development and innovation potential for the healthcare sector. When considering how best to grow clinical trial operations for 2022 and beyond, Labcorp Drug Development sought to leverage existing location advantages with new opportunities …
PK, PD and immunogenicity assays to support clinical trials – building the bigger picture
Understanding how a body processes a therapy and a therapy’s effect on the body is a critical step for understanding safety and efficacy to support clinical trials. But the process of characterization differs between small-molecule therapies and biotherapeutics. Associate Director of Early Scientific Engagement at Labcorp Drug Development, Robert Nelson, …
Learn about the latest in Labcorp DCT solutions by connecting with us at regional meetings around the globe – May 2022
Welcome to the May 2022 Labcorp Drug Development Decentralized Clinical Trial (DCT) blog. Because spring is a time traditionally packed with industry conferences, we will devote this blog to reviewing some of the highlights of our plans for the spring conference season. We hope to connect with you at one …
Non-GLP sample analysis for ocular biodistribution studies
Traditional bioanalytical service providers are geared toward analyzing large sets of samples under various regulatory guidelines, such as large nonclinical and clinical studies, which are heavily regulated. This puts a heavy burden on these service providers, creating long lead times, resource constraints and lack of flexibility. Currently, many bioanalytical laboratories …
Science that never sleeps
When you have a global footprint spanning every time zone, there’s no such thing as working from “9 to 5.” You just have to know how to work the clock. That’s the idea behind our Follow the Sun initiative. By creatively leveraging our global footprint, we can trim days off …
Special data effects that magically reveal your study side effects
In 2016, the Food and Drug Administration (FDA) made the move to digitization by requiring the collection and submission of datasets for nonclinical studies to be filed electronically in a standardized, consistent format. Known as the Clinical Data Interchange Standards Consortium (CDISC) Standard for Exchange of Nonclinical Data (SEND), this …
Welcome to the digital future of pathology
Imagine getting a phone call in the middle of your study from a scientist who is seeing something completely unexpected in your study results. You need to make a decision on how to move forward and you need to do it quickly. You don’t have time to wait for a …
Harnessing efficiencies and intelligence for your study
Let us pull back the curtain for just a moment. There are hundreds, if not thousands, of different actions and pieces of data that need to be completed, collected, processed, organized and tracked over the duration of your study or program. That information has to be accessible by dozens of …